frontotemporal dementia

AC Immune's ACI-19626 PET tracer demonstrates superior uptake in ALS patients versus controls, with positive safety data advancing Phase 1b expansion to neurodegeneration study.

Global dementia market expanding rapidly as disease-modifying treatments like LEQEMBI and KISUNLA shift focus from symptom management to early intervention for 55 million affected patients worldwide.

Takeda exits dementia drug partnership with Denali Therapeutics on DNL593. Denali regains full control, plans Phase 1/2 data release by end-2026. Denali shares fell 3.73%.